Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX)

Historical Holders from Q3 2016 to Q3 2025

Symbol
PTGX on Nasdaq
CUSIP
74366E102
Type / Class
Equity / Common Stock, par value $0.00001
Shares outstanding
62.2M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
70.7M
Holdings value
$4.7B
% of all portfolios
0.008%
Grand Portfolio weight change
+0%
Number of holders
273
Number of buys
123
Number of sells
-148
Average Value change %
0%
Average buys %
+0.001%
Average sells %
-0.002%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 13.8% -6.67% $570M -$33.8M 8.58M -5.6% BlackRock, Inc. Sep 30, 2025
Farallon Capital Partners, L.P. 9.99% $254M 5.96M Dapice Joshua J. Dec 31, 2024
STATE STREET CORP 5.2% +20% $147M $23M 3.21M +18.5% STATE STREET CORPORATION Jun 30, 2025
BIOTECHNOLOGY VALUE FUND L P 4.1% -22% $170M -$43.2M 2.56M -20.2% BVF PARTNERS L P/IL Sep 30, 2025
Deep Track Capital, LP 2.76% -50.6% $114M -$102M 1.72M -47.2% Deep Track Capital, LP Sep 30, 2025

Institutional Holders of Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 70.7M $4.7B +$3.97M $66.43 273
2025 Q2 71M $3.92B +$345M $55.27 272
2025 Q1 65M $3.14B +$117M $48.36 272
2024 Q4 63.3M $2.44B +$43.6M $38.60 240
2024 Q3 61.6M $2.77B -$40.7M $45.00 238
2024 Q2 59.1M $2.05B -$21.7M $34.65 189
2024 Q1 59.7M $1.73B +$61.1M $28.93 182
2023 Q4 43.2K $992K -$585K $22.93 1
2023 Q3 56.7M $946M -$60.7M $16.68 142
2023 Q2 56.7M $1.57B +$104M $27.62 163
2023 Q1 53.2M $1.22B +$180M $23.00 133
2022 Q4 48.9M $533M +$12.5M $10.91 134
2022 Q3 47.2M $398M -$36.9M $8.43 127
2022 Q2 53.4M $422M -$73M $7.91 125
2022 Q1 50.3M $1.19B +$11.4M $23.68 135
2021 Q4 49.1M $1.68B +$93.9M $34.20 142
2021 Q3 46.2M $818M -$247M $17.72 127
2021 Q2 48M $2.15B +$180M $44.88 136
2021 Q1 43.8M $1.13B +$29.7M $25.90 123
2020 Q4 40.3M $812M +$97.7M $20.16 119
2020 Q3 37.2M $727M +$62.3M $19.55 90
2020 Q2 33.2M $586M +$211M $17.66 80
2020 Q1 22.3M $158M +$1.1M $7.06 73
2019 Q4 23.1M $163M +$7.99M $7.05 75
2019 Q3 18.9M $227M +$20.8M $12.01 69
2019 Q2 17.2M $208M +$26.4M $12.11 62
2019 Q1 15.1M $189M +$22.1M $12.57 62
2018 Q4 13.9M $93.2M -$9.55M $6.73 62
2018 Q3 16M $164M +$27M $10.29 59
2018 Q2 13.9M $93.6M +$10.9M $6.72 68
2018 Q1 11.9M $103M -$12M $8.59 67
2017 Q4 11.8M $246M +$77.2M $20.80 64
2017 Q3 8.13M $144M +$629K $17.67 41
2017 Q2 8.11M $91.8M -$283K $11.31 39
2017 Q1 8.01M $103M +$4.47M $12.81 39
2016 Q4 7.98M $175M +$2.37M $21.99 38
2016 Q3 6.9M $145M +$145M $21.13 34